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Introduction
Ever since the first diagnosis of Alzheimer's disease (AD), the three histological hallmarks (plaques, neurofibrillary tangles and neurodegeneration) underlying the changes in memory and behavior have been studied intensively. The amyloid beta (Ab) protein, the main component of plaques, has been a key target since its discovery (Masters et al., 1985) . The amount of insoluble Ab fibrils, i.e. the main component of plaques, does not correlate well with disease progression. Instead, accumulating evidence indicate that the level of soluble Ab oligomers (Abo) and protofibrils correlate with disease stage (McLean et al., 1999; N€ aslund et al., 2000) . Also post-mortem studies have found higher Ab oligomerto-plaque ratios in demented patients than in non-demented patients with Ab plaque pathology (Esparza et al., 2013; Santos et al., 2012) .
Monitoring disease progression over time is not feasible with conventional histological methods, as these are performed on postmortem tissue samples. Nor do biomarkers in CSF such as Ab42, tau or phosphor-tau change in relation to disease progression (Grossman et al., 2005; Lin et al., 2009; Mehta et al., 2001; Wallin et al., 2011) . This has led to the development of imaging based techniques to observe AD pathology in vivo. [
11 C]PIB is the most widely used positron emission tomography (PET) radioligand for visualizing Ab plaque load in the human brain in vivo (Klunk et al., 2004) . The downside to this radioligand and other PET-ligands targeting fibrillar amyloid is the inability to quantify disease progression as their signal, in line with CSF biomarkers, saturates rapidly, leaving it therefore mainly suitable for a binary assessment of Ab plaque presence (Engler et al., 2006) .
As such, it is of great interest to assess the viability of alternative PET radioligands for measuring disease stage severity. Further, more dynamic markers may also be used to quantify the efficacy of novel treatments. A prerequisite to do this is to find a target (i.e. a receptor or a protein) of which the expression would change with disease severity.
One of the earliest signs of AD pathology is an impairment of memory, possibly due to synaptic dysfunction and loss caused by Abo (Klein, 2001) . Abo also alter synaptic plasticity, inhibit longterm potentiation (LTP) (Nomura et al., 2012; Walsh et al., 2002) ; and facilitate long-term depression (LTD) (Wang et al., 2002) . The mechanisms by which Abo initiate pathology involve binding to excitatory synapses and disrupting synaptic function (Lacor et al., 2004) .
The metabotropic glutamate receptor 5 (mGluR5) is a postsynaptically expressed G-protein coupled receptor involved in Ca2þ regulation (Abe et al., 1992) , and plays an essential role in modulating synaptic strength in the adult brain (Jong et al., 2009 ). Presenilin-1 (PS1) deficient neurons have decreased glutamate uptake and lower cell surface expression of neuronal glutamate receptor EEAC1 compared to wild type (wt) neurons and similar effects are seen with gamma-secretase inhibitor treatment (Yang et al., 2004 ). Renner and colleagues reported an interaction between Abo and mGluR5, whereby the Ab oligomers perturb synaptic functioning by binding to them. Following the interaction with the synapse by the Abo, individual mGlu5 receptors are hindered in their diffusion laterally and cluster; which leads to elevated intracellular calcium and synaptotoxicity (Renner et al., 2010) . At the post-synaptic density, Abo bind with high affinity to Cellular Prion Protein (PrP C ) (Laur en et al., 2009 ). This pathology causing complex requires the presence of mGluR5 in order for AboPrP C to interact with Fyn and mediate an increase of intracellular calcium (Um et al., 2013) . In a transgenic mouse model overexpressing amyloid b protein precursor (AbPP), mGluR5 levels were increased in the CA3 region of the hippocampus and toxicity was caused by increased calcium flux (Overk et al., 2014) . Hamilton et al. crossed the AbPP Swe /PS1 DE9 AD mouse model with an mGluR5 null mouse line, and the genetic deletion of mGluR5 reversed the spatial memory deficit observed in AbPP Swe /PS1 DE9 mice; furthermore, the AD mice showed increased mGluR5 expression on the cell surface, but no increase in total levels in brain lysate (Hamilton et al., 2014) . Previously however, an increase in mGluR5 expression by Ab has been reported, but this was in cultured astrocytes (Casley et al., 2009) . Antagonists for mGluR5 also reversed learning and memory deficits in AD mouse models, and synaptic markers recovered after a 10-day treatment with an mGluR5 antagonist (Um et al., 2013) . In AD patients, metabotropic glutamate receptor binding was decreased in frontal cortex directly correlating to Braak stage progression (Albasanz et al., 2005) . Altogether mGluR5 seems to play an integral role in the development of Abo pathology, and may prove to be a potential biomarker for disease progression. The aim of the present study was to investigate the expression of mGluR5 during disease progression in a transgenic mouse model overexpressing human AbPP ArcSwe (tg-ArcSwe) (Lord et al., 2006) . In addition to in vitro quantification of mGluR5 using different immunoassay techniques, expression and function of mGluR5 during disease progression was investigated in vivo using [ 11 C] ABP688, a novel PET ligand with high affinity and selectivity for mGluR5 (Ametamey et al., 2006) .
Material and methods

Animals
All procedures described in this paper were approved by the (Lord et al., 2009 (Lord et al., , 2006 Philipson et al., 2009) . Wild type littermates were used as control animals (wt). Animals were housed with ad libitum access to food and water in rooms with a maintained consistent temperature and humidity in an animal facility at Uppsala University.
Synthesis of [
and O-desmethyl ABP688 (3-((6-methylpyridin-2-yl)ethynyl)cyclohex-2-en-1-one oxime) as a 12:1 mixture of E/Z enantiomers were obtained from ABX (Radeberg, Germany). All reagents and solvents used in the radiosyntheses were supplied by Aldrich and used as received. The production of [ 11 C]ABP688 was performed according to a previously published method with modifications (Ametamey et al., 2006) .
Cyclotron produced [ (1.0 mg, 4.4 mmol) and NaOH (3.0 mL, 5.0 M, 15 mmol) in anhydrous dimethylformamide (250 mL). The reaction mixture was heated at 90 C for 5 min, diluted with water (500 mL) and the product was purified by semi-preparative radio/UV-HPLC (Column: Phenomenex Luna, 10m, C18(2), 250 Â 10 mm; Eluent: ammonium formate pH 3.5 (50 mM)/acetonitrile 55/45; 5 mL/min). [ 11 C]ABP688 eluted at 12.7 min and the collected fraction was diluted with water (20 mL) and passed over a solid phase extraction (SPE) cartridge (Sep-Pak tC18 Plus Light Cartridge) followed by a wash with 20% ethanol in water (20 mL) to remove the HPLC mobile phase and polar impurities. The product (3.1 ± 0.7 GBq) was eluted from the SPE-cartridge with 99.5% ethanol (0.2 mL) and reformulated in phosphate buffered saline pH 7.4 (2 mL) and Kleptose ® (0.1 mL, hydroxypropyl betacyclodextrin 300 mg/mL in sodium chloride 9 mg/mL). The synthesis time from end of radionuclide production to formulated product was approximately 40 min. The radiochemical purity was 97.4 ± 0.9% as assessed by analytical radio/UV-HPLC (Column: Phenomenex Chromolith Performance RP-18e, 100 Â 4.6 mm; Eluent: ammonium formate pH 3.5 (50 mM)/acetonitrile 55/45; 5 mL/min). The identity of the product was confirmed by comparing the retention time (5.9 min) with authentic ABP688. The specific radioactivity was determined by the same HPLC method as used for the assessment of radiochemical and chemical purity.
PET
PET was performed in mice using a preclinical Triumph micro LabPet/CT. The animals (wt C57BL/6 and transgenic ArcSwe strain at either 4, 8 or 16 months of age) were anesthetized with isoflurane prior to administration of [ 11 C]ABP688 (mean injected activity of 9.7 ± 5.7 MBq, mean specific activity of 19.9 ± 25.0 GBq/ mmol at time of injection, transgenic and control mice were injected with 63 ± 46 and 37 ± 35 nmol/kg respectively) by tail vein injection. Scan duration was 30 min, and breathing frequency was monitored and maintained at 50e70 breaths per minute. Mice were scanned between 10 a.m.e2 p.m. PET data were acquired in list mode and reconstructed in user-defined time frames (6 $ 10 s, 3 $ 60 s, 5 $ 5 min) using a MLEM 2D algorithm. Following the PET scan, a CT scan was performed (Field of View: 80 mm).
PET analysis
Image files were evaluated by region-of-interest (ROI) analysis using AMIDE (Loening and Gambhir, 2003) . ROIs were drawn manually once based on the M. Mirrione T2-weighted MRI VOI template found in Pmod (PMOD Technologies Ltd., Zürich, Switzerland), then manually co-registered with each study using the CT as reference (Ma et al., 2005; Mirrione et al., 2007) . Regional time-activity curves (TAC) based on ROIs were calculated for the following brain regions: hippocampus (20.4 mm 3 ), striatum (20.2 mm 3 ), whole brain (312.4 mm 3 ), and cerebellum (46.5 mm 3 ).
Regional BP nd were obtained with Pmod using the simplified reference tissue model (SRTM) with the cerebellum as reference region (Elmenhorst et al., 2010; Lammertsma and Hume, 1996) .
Brain extraction and ex vivo studies
Following the PET scan, animals were anesthetized with isoflurane (3.5%) and intracardially perfused with 50 mL of 37 C physiological saline. After extracting the brain, hemispheres were divided: The left hemisphere was snap frozen with dry ice and stored at À70 C, and the right hemisphere was left in 4% paraformaldehyde in PBS for 24 h, followed by a sucrose gradient immersion. The left hemisphere was then homogenized with a tissue grinder with teflon pestle (2$10 strokes) in a 1:5 tissue:Tris-acetate buffer (50 mM, pH 7.4) weight:volume ratio with complete protease inhibitors (Roche).
In addition, radioactivity in blood samples and in the frozen brain hemisphere were measured with a g-counter (1480 Wizard, Wallac Oy, Turku, Finland) as follows:
In order to obtain membrane fractions, 300 mL of sample homogenate was purified by differential centrifugation. Homogenate was spun down at 1000 Â g for 10min. Supernatants were then centrifuged at 14,000 Â g for 20 min at 4 C. Pellet (P2) was defined as the crude synaptosomal fraction (M enard and Quirion, 2012), resuspended in 300 mL TBS, and then used for immunoblotting.
Immunoblotting
The P2 sample (15 mL) 
Protofibril ELISA
Ab protofibril levels in brain homogenate were measured as previously described (Englund et al., 2007; Sehlin et al., 2016) . In brief, plates coated overnight with 200 ng/well mAb158 and then blocked with 1% BSA in PBS, were incubated with TBS extract (1:25) at RT for 2 h; followed by detection with biotinylated mAb158
(0.5 mg/mL), and SA-HRP (1:2000, Mabtech AB). Signal was developed with K blue aqueous TMB substrate (Neogen Corp., Lexington, KY, USA) and development was halted by adding sulfuric acid. Wells were then read with a spectrophotometer set to 450 nm.
Immunofluorescence
The right hemisphere was cut into 20 mm thick sagittal sections in a cryostat and mounted onto Superfrost ® Plus glass slides (Menzel-Glaser, Germany). Sections were rinsed in PBS and then incubated with 5% normal goat serum (Vector Laboratories Inc.) and 0.1% Triton X-100 in PBS. This was followed by an overnight incubation at 4 C with mouse a-GFAP (1:400, G3893, SigmaAldrich) and rabbit a-mGluR5 (1:200, [EPR2425Y] ab76316, abcam). After a series of PBS washes, slides were incubated with goat a-mouse AF488 (1:500, A11001, Life Technologies) and goat arabbit AF555 (1:300, A21429, Life Technologies) for 1 h at room temperature. The sections were then mounted with DAPI containing Vectashield (Vector Laboratories Inc.) and left to air dry in the dark.
Statistics
The result values are given as mean ± s.e.m. in GraphPad Prism 6 using one or two-way ANOVA, followed by post hoc Tukey's if there was significance. Variance was assumed to be equal between groups. 3.1 ± 0.7 GBq was obtained 40 min after the end of the radionuclide production. The radiochemical purity was 97.4 ± 0.9%.
Results
[ 11 C]ABP688 synthesis
[ 11 C]ABP688 uptake in brain
To investigate mGluR5 distribution in the brain, wt and tgArcSwe mice were administered with [ 11 C]ABP688 and PET scanned for 30 min. A typical distribution pattern with high signal in the hippocampus is shown in Fig. 1a , corresponding to an earlier validation study performed in rats (Elmenhorst et al., 2010) . When excess of isotopically unmodified (unlabeled) ABP688 was coinjected with [ 11 C]ABP688, the distinctive pattern of these receptor rich regions disappeared (Fig. 1b) .
To investigate age and genotype-dependent changes in receptor binding, PET data was quantified as nondisplaceable binding potential (BP nd ) in several regions known for high mGluR5 expression in the brain by using the simplified tissue reference model, with the cerebellum as reference region (Fig. 2) . The regions of interest were hippocampus (a), thalamus (b), striatum (c), and the whole brain excluding the cerebellum (d). The BP nd in the mGluR5 rich regions hippocampus, thalamus, and striatum were higher than in the whole brain. No effect of genotype on BP nd in the brain was observed. However younger animals appeared to have slightly higher BP nd in the thalamus than older animals (observed trend, p ¼ 0.10).
Ex vivo radioactivity
The radioactivity in brain (Fig. 3 a-c ) and blood (d-e) tissue isolated after the PET scan was measured, and the brain-to-blood concentration ratio of activity was found to be similar in all age and genotype groups. The level of activity in the blood (measured as % injected dose and SUV) remained consistent with age and genotype as well.
Protofibril levels in brain
As a measurement of Ab pathology, mouse brain tissue homogenate obtained from the PET scanned mice was analyzed with ELISA for levels of soluble Ab protofibrils. Tg-ArcSwe mice displayed accumulating Ab protofibril levels as they aged (Fig. 4) , while background signals were found in wt mice of all ages. 
mGluR5 immunoblotting
To investigate protein levels in the brain of tg-ArcSwe and wt mice at different ages, we performed mGluR5 immunoblotting on the brain tissue obtained post-scan, resulting in two main findings. First, the amount of mGluR5 in wt mice decreased with age (Fig. 5) . This was not, however, found in tg-ArcSwe mice as they appeared to express relatively constant mGluR5 levels at 4, 8, and 16 months. Second, at all ages the tg-ArcSwe mice had higher mGluR5 levels than wt mice, but this difference was only significant in the 16 month group.
mGluR5 immunofluorescence
In a separate group of animals, brain sections were coimmunostained for mGluR5 and GFAP immunofluorescence and we investigated the CA3 region of the hippocampus, where previously it has been reported that mGluR5 is found to be upregulated by Ab (Casley et al., 2009) . Intensity quantification of the mGluR5 signal found a significant decrease in 12 month old wt mice compared with age-matched tg-ArcSwe littermates, and 16 month old wt mice. The mGluR5 signal also appeared to strongly coincide with GFAP immunofluorescence (Fig. 6) .
Discussion
The present study aimed at investigating the changes in mGluR5 expression during disease progression in the tg-ArcSwe mouse model of AD and to study whether these changes could be imaged with PET radioligand [
11 C]ABP688 as a potential biomarker for disease stage in AD. Previous studies have pointed towards an involvement of mGluR5 in the synaptotoxicity caused by Abo (Lacor et al., 2004; Nomura et al., 2012; Walsh et al., 2002; Wang et al., 2002) . To some extent, the present study confirmed previous reports of differences in mGluR5 expression between wt mice and animals with Ab pathology. Semi-quantitative analysis of mGluR5 expression using immunohistochemistry also showed a significant increase of mGluR5 in the 12 months tg-ArcSwe mice compared to wt mice at 12 months of age. Another interesting finding, also in line with previous studies (Shrivastava et al., 2013) , showed that mGluR5 tended to cluster close to GFAP positive astrocytes. It has been reported that astrocytic mGluR5 is upregulated by Ab (Casley et al., 2009) .
Levels of mGluR5, quantified with immunoblotting, in mouse brain were found to be higher in tg-ArcSwe mice than in wt mice. An age-related decrease in mGluR5 level in wt mice was observed with immunoblotting. Such a decrease was less apparent in tgArcSwe mice. We speculate that the decrease observed in the wt mice may be due synaptic loss in the hippocampus as part of agedependent decay in LTP and memory function (Bach et al., 1999; Detoledo-Morrell et al., 1988) . Although this process is likely to also take place in the tg-ArcSwe brain, it is less evident from our data possibly due to the overexpression and aberrant behavior of mGluR5.
Tg-ArcSwe mice have elevated Ab protofibril levels starting already at an age of 4 months as found previously (Sehlin et al., 2016) . Plaque formation starts around 6 months and the pathology develops fairly slowly compared to for example the most commonly used AD mouse model, Tg2576 (Frautschy et al., 1998; Lord et al., 2006) . The increase in age-related Ab protofibril concentration coincides with the retention of elevated mGluR5 levels, unlike in wt mice which have neither Ab protofibrils nor increased levels of mGluR5. It is possible that Ab protofibrilmediated clustering and accumulation of mGluR5 leads to elevated amounts of aberrantly functioning mGluR5, likely at the post-synaptic density. This pool of mGluR5 then is part of the pathological process, while in wt mice the age-related decrease may be due to senescent synapse loss.
To our knowledge this is the first study of mGluR5 in vivo in an AD model. Previously, the interaction between mGluR5 and Ab has been investigated in fmr-1 KO mice, in AbPP Swe /PS1, and in mGluR5 KO mice, however these were all ex vivo experiments (Hamilton et al., 2014; Westmark and Malter, 2007) . PET scans were performed in 4, 8, and 16 month old mice. We found higher BP nd in the hippocampus, striatum, and thalamus than in the whole brain. This goes in line with the expression pattern of mGluR5 in brain, which has been reported to be highest in hippocampus, and moderate in striatum and thalamus in human (Daggett et al., 1995) . The binding in these receptor rich areas could be blocked with unlabeled ABP688 showing the specificity of the ligand.
The age and genotype differences assessed with immunoblotting could not be visualized with PET in any of the regions studied. Evidently, the Ab-related changes in mGluR5 are not reflected in changes in BP nd . Potentially it may be that while receptor protein levels are increased in tg-ArcSwe mice, ABP688 is unable to bind this mGluR5 fraction because of mGluR5 clustering and formation of complexes, as previously reported (Renner et al., 2010; Um et al., 2013) . Although 28 animals were scanned in total, they were for analysis, divided into 6 groups and hence the fairly small group sizes may also limit the possibility to observe small age and genotype dependent differences.
Another explanation would be the limitation of performing PET on small animals. One such limitation is the spatial resolution of PET, as the mouse brain is small, and hence, the PET image resolution (1e3 mm) may not be sufficient. With the current low resolution and small mouse brain, the partial volume effect also plays an even larger role in muddling activity levels. Furthermore, it may be that changes in mGluR5 expression are too small to capture with our current approach. Recently, it was found that using ultrahigh specific activity (3515e9620 GBq/mmol) improves visualization and specific binding in a small-animal PET study for mGluR1 in rat brain using [ 11 C]ITMM compared with a more conventional SA (74e174 GBq/mmol) (Yamasaki et al., 2016) .
Conclusion
All in all, [
11 C]ABP688 appears to be a tracer with high specificity for mGluR5. However, currently quantifying mGluR5 has been proven to be difficult in mice, at least in our tg-ArcSwe model used here, although our data acquired from post-mortem tissue suggests that Ab pathology may affect the levels of mGluR5. The study showed that mGluR5 is likely to be upregulated in tg-ArcSwe mice already before plaque formation, with the most pronounced difference found between genotypes at 16 months of age.
Nonetheless, [ 11 C]ABP688 appears to be a specific tracer for imaging of mGluR5 and we found typical tracer distribution corresponding with regions known to be high in mGluR5 expression in our transgenic and wt mice. . Left: Coronal section from a 4 months old wt mouse brain in the CA3 region of the hippocampus. GFAP (green) staining visualizes astrocytes, mGluR5 is shown in red. Arrow points at a concentrated mGluR5 local intensity nearby an astrocyte (40Â magnification). Right: Intensity quantification of mGluR5 in the stratum radiatum of the hippocampus. Transgenic ArcSwe mice have displayed higher mGluR5 intensity at 12 months of age compared to wt (p < 0.01). Bars are displayed as mean ± standard error of the mean (s.e.m.). The number of animals per group was 5, except for the 12 month old tg-ArcSwe mice where n ¼ 4. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
